- Home
- AUPH vs PEB Comparison
AUPH vs PEB Comparison
Compare AUPH & PEB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- PEB
- Stock Information
- Founded
- AUPH 1993
- PEB 2009
- Country
- AUPH Canada
- PEB United States
- Employees
- AUPH N/A
- PEB N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- PEB Real Estate Investment Trusts
- Sector
- AUPH Health Care
- PEB Real Estate
- Exchange
- AUPH Nasdaq
- PEB Nasdaq
- Market Cap
- AUPH 1.4B
- PEB 1.2B
- IPO Year
- AUPH 1999
- PEB 2009
- Fundamental
- Price
- AUPH $12.83
- PEB $12.08
- Analyst Decision
- AUPH Strong Buy
- PEB Hold
- Analyst Count
- AUPH 3
- PEB 7
- Target Price
- AUPH $12.00
- PEB $12.33
- AVG Volume (30 Days)
- AUPH 1.5M
- PEB 3.0M
- Earning Date
- AUPH 11-06-2025
- PEB 11-05-2025
- Dividend Yield
- AUPH N/A
- PEB 0.35%
- EPS Growth
- AUPH N/A
- PEB N/A
- EPS
- AUPH 0.42
- PEB N/A
- Revenue
- AUPH $260,111,000.00
- PEB $1,469,933,000.00
- Revenue This Year
- AUPH $16.92
- PEB $2.18
- Revenue Next Year
- AUPH $14.43
- PEB $2.96
- P/E Ratio
- AUPH $29.12
- PEB N/A
- Revenue Growth
- AUPH 25.59
- PEB 2.00
- 52 Week Low
- AUPH $6.55
- PEB $7.42
- 52 Week High
- AUPH $12.90
- PEB $15.12
- Technical
- Relative Strength Index (RSI)
- AUPH 63.83
- PEB 68.73
- Support Level
- AUPH $12.18
- PEB $11.26
- Resistance Level
- AUPH $12.90
- PEB $11.90
- Average True Range (ATR)
- AUPH 0.42
- PEB 0.35
- MACD
- AUPH -0.06
- PEB 0.02
- Stochastic Oscillator
- AUPH 92.89
- PEB 87.32
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About PEB Pebblebrook Hotel Trust of Beneficial Interest
Pebblebrook Hotel Trust currently owns upper upscale and luxury hotels with 11,933 rooms across 46 hotels in the United States. Pebblebrook acquired LaSalle Hotel Properties, which owned 10,451 rooms across 41 US hotels, in November 2018, though management has sold many of those hotels over the past few years. Pebblebrook's portfolio consists mostly of independent hotels with no brand affiliations, though the combined company does own and operate some hotels under Marriott, Starwood, InterContinental, Hilton, and Hyatt brands.